Literature DB >> 19255780

Expression of ADAMs ("a disintegrin and metalloprotease") in the human lung.

Antoon Dijkstra1, Dirkje S Postma, Jacobien A Noordhoek, Monique E Lodewijk, Henk F Kauffman, Nick H T ten Hacken, Wim Timens.   

Abstract

In view of the associations of "a disintegrin and metalloprotease" (ADAM) with respiratory diseases, we assessed the expression of various ADAMs in human lung tissue. Lung tissue was obtained from nine individuals who underwent surgery for lung cancer or underwent lung transplantation for emphysema. Also, 16HBE 14o- (human bronchial epithelial) and A549 (alveolar type II epithelium-like) cell lines were used. Immunohistochemistry was performed with antibodies recognizing different ADAM domains. The ADAMs were typically distributed over the bronchial epithelium. ADAM8 and ADAM10 were expressed diffusely in all layers of the epithelium. ADAM9, ADAM17, and ADAM19 were predominantly expressed in the apical part of the epithelium, and ADAM33 was predominantly and strongly expressed in basal epithelial cells. In smooth muscle, ADAM19 and ADAM17 were strongly expressed, as was ADAM33, though this expression was weaker. ADAM33 was strongly expressed in vascular endothelium. All ADAMs were generally expressed in inflammatory cells. The typical distribution of ADAMs in the lung, especially in the epithelium, is interesting and suggests a localized function. As most ADAMs are involved in release of (pro-) inflammatory mediators and growth factors, they may play an important role in the first line of defense and in initiation of repair events in the airways.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255780     DOI: 10.1007/s00428-009-0748-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  48 in total

1.  Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma.

Authors:  H Jongepier; H M Boezen; A Dijkstra; T D Howard; J M Vonk; G H Koppelman; S L Zheng; D A Meyers; E R Bleecker; D S Postma
Journal:  Clin Exp Allergy       Date:  2004-05       Impact factor: 5.018

Review 2.  ADAMs: key components in EGFR signalling and development.

Authors:  Carl P Blobel
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

Review 3.  ADAMs: focus on the protease domain.

Authors:  R A Black; J M White
Journal:  Curr Opin Cell Biol       Date:  1998-10       Impact factor: 8.382

4.  ADAM33 expression in asthmatic airways and human embryonic lungs.

Authors:  Hans Michael Haitchi; Robert M Powell; Timothy J Shaw; Peter H Howarth; Susan J Wilson; David I Wilson; Stephen T Holgate; Donna E Davies
Journal:  Am J Respir Crit Care Med       Date:  2005-02-11       Impact factor: 21.405

Review 5.  Stem cell factor: a hemopoietic cytokine with important targets in asthma.

Authors:  S H P Oliveira; N W Lukacs
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2003-12

6.  The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity.

Authors:  Mohita J Mohan; Theresa Seaton; Justin Mitchell; Anne Howe; Kevin Blackburn; William Burkhart; Mary Moyer; Inder Patel; Gregory M Waitt; J David Becherer; Marcia L Moss; Marcos E Milla
Journal:  Biochemistry       Date:  2002-07-30       Impact factor: 3.162

7.  Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness.

Authors:  Paul Van Eerdewegh; Randall D Little; Josée Dupuis; Richard G Del Mastro; Kathy Falls; Jason Simon; Dana Torrey; Sunil Pandit; Joyce McKenny; Karen Braunschweiger; Alison Walsh; Ziying Liu; Brooke Hayward; Colleen Folz; Susan P Manning; Alicia Bawa; Lisa Saracino; Michelle Thackston; Youssef Benchekroun; Neva Capparell; Mei Wang; Ron Adair; Yun Feng; JoAnn Dubois; Michael G FitzGerald; Hui Huang; René Gibson; Kristina M Allen; Alex Pedan; Melvyn R Danzig; Shelby P Umland; Robert W Egan; Francis M Cuss; Steuart Rorke; Joanne B Clough; John W Holloway; Stephen T Holgate; Tim P Keith
Journal:  Nature       Date:  2002-07-10       Impact factor: 49.962

8.  Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity.

Authors:  M Roghani; J D Becherer; M L Moss; R E Atherton; H Erdjument-Bromage; J Arribas; R K Blackburn; G Weskamp; P Tempst; C P Blobel
Journal:  J Biol Chem       Date:  1999-02-05       Impact factor: 5.157

9.  An essential role for ectodomain shedding in mammalian development.

Authors:  J J Peschon; J L Slack; P Reddy; K L Stocking; S W Sunnarborg; D C Lee; W E Russell; B J Castner; R S Johnson; J N Fitzner; R W Boyce; N Nelson; C J Kozlosky; M F Wolfson; C T Rauch; D P Cerretti; R J Paxton; C J March; R A Black
Journal:  Science       Date:  1998-11-13       Impact factor: 47.728

10.  Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1).

Authors:  Q Yuan; K F Austen; D S Friend; M Heidtman; J A Boyce
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

View more
  38 in total

Review 1.  The role of the epithelium in airway remodeling in asthma.

Authors:  Donna E Davies
Journal:  Proc Am Thorac Soc       Date:  2009-12

2.  Dendritic cells from aged subjects contribute to chronic airway inflammation by activating bronchial epithelial cells under steady state.

Authors:  S Prakash; S Agrawal; H Vahed; M Ngyuen; L BenMohamed; L BenMohamad; S Gupta; A Agrawal
Journal:  Mucosal Immunol       Date:  2014-04-23       Impact factor: 7.313

3.  Overexpression of a disintegrin and metalloprotease 8 in human gliomas is implicated in tumor progression and prognosis.

Authors:  Shiming He; Lianshu Ding; Yizhan Cao; Gang Li; Jianping Deng; Yanyang Tu; Boliang Wang
Journal:  Med Oncol       Date:  2011-10-09       Impact factor: 3.064

4.  Upregulation of a disintegrin and metalloprotease 8 influences tumor metastasis and prognosis in patients with osteosarcoma.

Authors:  Zhehai Li; Qiande Liao; Yuchi Wu; Mingmei Liao; Yuqin Hao; Shengbin Zhang; Shipeng Song; Bing Li; Yang-de Zhang
Journal:  Pathol Oncol Res       Date:  2012-01-05       Impact factor: 3.201

5.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

6.  A Six-SNP haplotype of ADAM33 is associated with asthma in a population of Cartagena, Colombia.

Authors:  Candelaria I Vergara; Nathalie Acevedo; Silvia Jiménez; Beatriz Martínez; Dilia Mercado; Leonor Gusmão; Kathleen C Barnes; Luis Caraballo
Journal:  Int Arch Allergy Immunol       Date:  2009-11-24       Impact factor: 2.749

7.  Adam8 limits the development of allergic airway inflammation in mice.

Authors:  Martin D Knolle; Takahiro Nakajima; Anja Hergrueter; Kushagra Gupta; Francesca Polverino; Vanessa J Craig; Susanne E Fyfe; Muhammad Zahid; Perdita Permaul; Manuela Cernadas; Gilbert Montano; Yohannes Tesfaigzi; Lynette Sholl; Lester Kobzik; Elliot Israel; Caroline A Owen
Journal:  J Immunol       Date:  2013-05-13       Impact factor: 5.422

Review 8.  ADAM8: a new therapeutic target for asthma.

Authors:  Martin D Knolle; Caroline A Owen
Journal:  Expert Opin Ther Targets       Date:  2009-05       Impact factor: 6.902

9.  A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells.

Authors:  Jessica Pruessmeyer; Christian Martin; Franz M Hess; Nicole Schwarz; Sven Schmidt; Tanja Kogel; Nicole Hoettecke; Boris Schmidt; Antonio Sechi; Stefan Uhlig; Andreas Ludwig
Journal:  J Biol Chem       Date:  2009-10-29       Impact factor: 5.157

Review 10.  Role of ADAM and ADAMTS metalloproteinases in airway diseases.

Authors:  Genevieve Paulissen; Natacha Rocks; Maud M Gueders; Celine Crahay; Florence Quesada-Calvo; Sandrine Bekaert; Jonathan Hacha; Mehdi El Hour; Jean-Michel Foidart; Agnes Noel; Didier D Cataldo
Journal:  Respir Res       Date:  2009-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.